Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data
Sign Up to like & getrecommendations! Published in 2022 at "Healthcare"
DOI: 10.3390/healthcare10081400
Abstract: Background: Little is known regarding the safety of direct-acting antivirals (DAA), even though they are widely used. This study aims to evaluate the adverse events of DAA using post-market data. Methods: FDA Adverse Events Reporting… read more here.
Keywords: reported using; post market; adverse events; using harvoni ... See more keywords